Teriflunomide: an oral therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis
GD Costa, G Comi - Expert review of neurotherapeutics, 2023 - Taylor & Francis
Introduction Different disease-modifying therapies (DMTs) have been developed to slow
down the progression of pediatric multiple sclerosis (MS). Teriflunomide is one such DMT …
down the progression of pediatric multiple sclerosis (MS). Teriflunomide is one such DMT …
Narrative review based on fingolimod therapy in pediatric MS
B Piri Cinar, B Konuskan, B Anlar… - SAGE Open …, 2023 - journals.sagepub.com
The course of pediatric-onset multiple sclerosis and adult multiple sclerosis shows some
clinical differences. The rate of having a second attack after the first clinical event is 80% in …
clinical differences. The rate of having a second attack after the first clinical event is 80% in …
Old and New Strategies in the Treatment of Pediatric Multiple Sclerosis: A Personal View for a New Treatment Approach
A Ghezzi - Neurology and Therapy, 2024 - Springer
Up to 10 years ago the most common approach to the treatment of pediatric MS (ped-MS)
was to start with IFNB or GA (so-called first-line therapies or moderate-efficacy disease …
was to start with IFNB or GA (so-called first-line therapies or moderate-efficacy disease …
Narrative review based on fingolimod therapy in pediatric MS.
B Konuskan, B Anlar, S Ozakbas - SAGE Open Medicine, 2023 - europepmc.org
The course of pediatric-onset multiple sclerosis and adult multiple sclerosis shows some
clinical differences. The rate of having a second attack after the first clinical event is 80% in …
clinical differences. The rate of having a second attack after the first clinical event is 80% in …